[1] Dy GK,Adjei AA.Understanding,recognizing,and managing toxicities of targeted anticancer therapies［J］.CA Cancer J Clin,2013,63(4):249-279.
[2] Sekine I,Takiguchi Y.Clinical classification of targeted agents used for anticancer treatment［J］.Tohoku J Exp Med,2013，230(1):1-5.
[3] Zhang Baihong,Yue Hongyun.Study progress of cancer therapeutic targets ［J］.Modern Oncology,2015,23（7）：1012-1016.［张百红，岳红云.肿瘤新治疗靶标的研究进展［J］.现代肿瘤医学,2015,23（7）：1012-1016.］
[4] Sliwkowski MX,Mellman I.Antibody therapeutics in cancer［J］.Science,2013,341(6151):1192-1198.
[5] Takenaga M,Yamamoto Y,Takeuchi T,et al.Potential new chemotherapy strategy for human ovarian carcinoma with a novel KSP inhibitor［J］.Biochem Biophys Res Commun,2015,463(3):222-228.
[6] Song M,Kim SH,Yoon SK.Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion.An example of swift repositioning［J］.Arch Pharm Res,2015,38(12):2120-2123.
[7] Vail ME,Murone C,Tan A,et al.Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment［J］.Cancer Res,2014,74(16):4470-4481.
[8] Gerald D,Chintharlapalli S,Augustin HG,et al.Angiopoietin-2:An attractive target for improved antiangiogenic tumor therapy［J］.Cancer Res,2013,73(6):1649-1657.
[9] Motzer RJ,Nosov D,Eisen T,et al.Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma:Results from a phase Ⅲ trial［J］.J Clin Oncol,2013,31(30):3791-3799.
[10] Fuchs CS,Tomasek J,Yong CJ,et al.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma（REGARD):An international,randomised,multicentre,placebo-controlled,phase 3 trial［J］.Lancet,2014,383(9911):31-39.
[11] Reck M,Kaiser R,Mellemgaard A,et al.Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer（LUME-Lung 1):A phase 3,double-blind,randomised controlled trial［J］.Lancet Oncol,2014,15(2):143-155.
[12] Cunningham D,Wong RP,D'Haens G,et al.Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer［J］.Br J Cancer,2013,108(3):493-502.
[13] Fu J,Koul D,Yao J,et al.Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells［J］.Cancer Res,2013,73(10):3062-3074.
[14] Zhao W,Wang L,Han H,et al.1B50-1,a mAb raised against recurrent tumor cells,targets liver tumor-initiating cells by binding to the calcium channel α2δ1 subunit［J］.Cancer Cell,2013,23(4):541-556.
[15] Yoshida GJ,Saya H.Therapeutic strategies targeting cancer stem cells［J］.Cancer Sci,2016,107(1):5-11.
[16] Dragu DL,Necula LG,Bleotu C,et al.Therapies targeting cancer stem cells:Current trends and future challenges［J］.World J Stem Cells,2015,7(9):1185-1201.
[17] Justilien V,Fields AP.Molecular pathways:Novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells［J］.Clin Cancer Res,2015,21(3):505-513.
[18] Yu M,Bardia A,Aceto N,et al.Cancer therapy.Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility［J］.Science,2014,345(6193):216-220.
[19] Mikhail S,Albanese C,Pishvaian MJ.Cyclin-dependent kinase inhibitors and the treatment of gastrointestinal cancers［J］.Am J Pathol,2015,185(5):1185-1197.
[20] Law ME,Corsino PE,Narayan S.Cyclin-dependent Kinase inhibitors as anticancer therapeutics［J］.Mol Pharmacol,2015,88(5):846-852.
[21] Dickson MA.Molecular pathways:CDK4 inhibitors for cancer therapy［J］.Clin Cancer Res,2014,20(13):3379-3383.
[22] Okabe S,Tauchi T,Tanaka Y,et al.Efficacy of the polo-like kinase inhibitor rigosertib,alone or in combination with Abelson tyrosine kinase inhibitors,against break point cluster region-c-Abelson-positive leukemia cells［J］.Oncotarget,2015,6(24):20231-20240.
[23] Strebhardt K,Becker S,Matthess Y.Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery［J］.Expert Opin Drug Discov,2015,10(1):1-8.
[24] Buege M,Mahajan PB.Clinical trials of poly(ADP-Ribose) polymerase inhibitors for cancer therapy:A review［J］.Rev Recent Clin Trials,2015,10(4):326-339.
[25] Flaveny CA,Griffett K,El-Gendy Bel-D,et al.Broad anti-tumor activity of a small molecule that selectively targets the warburg effect and lipogenesis［J］.Cancer Cell,2015,28(1):42-56.
[26] Mateo J,Carreira S,Sandhu S,et al.DNA-Repair defects and olaparib in metastatic prostate cancer［J］.N Engl J Med,2015,373(18):1697-1708.
[27] Weinberg SE,Chandel NS.Targeting mitochondria metabolism for cancer therapy［J］.Nat Chem Biol,2015,11(1):9-15.
[28] Mashima T,Soma-Nagae T,Migita T,et al.TRIB1 supports prostate tumorigenesis and tumor-propagating cell survival by regulation of endoplasmic reticulum chaperone expression［J］.Cancer Res,2014,74(17):4888-4897.
[29] Sharma P,Allison JP.The future of immune checkpoint therapy［J］.Science,2015,348(6230):56-61.
[30] Haanen JB,Thienen HV,Blank CU.Toxicity patterns with immunomodulating antibodies and their combinations［J］.Semin Oncol,2015,42(3):423-428.
[31] Topalian SL,Drake CG,Pardoll DM.Immune checkpoint blockade:A common denominator approach to cancer therapy［J］.Cancer Cell,2015,27(4):450-461.
[32] Postow MA,Callahan MK,Wolchok JD.Immune checkpoint blockade in cancer therapy［J］.J Clin Oncol,2015,33(17):1974-1982.
[33] Lipson EJ,Forde PM,Hammers HJ,et al.Antagonists of PD-1 and PD-L1 in cancer treatment［J］.Semin Oncol,2015,42(4):587-600.
[34] Le DT,Uram JN,Wang H,et al.PD-1 blockade in tumors with mismatch-repair deficiency［J］.N Engl J Med,2015,372(26):2509-2520.
[35] Garon EB,Rizvi NA,Hui R,et al.Pembrolizumab for the treatment of non-small-cell lung cancer［J］.N Engl J Med,2015,372(21):2018-2028.
[36] Weiner GJ.Building better monoclonal antibody-based therapeutics［J］.Nat Rev Cancer,2015,15(6):361-370.
[37] Cheng CJ,Bahal R,Babar IA,et al.MicroRNA silencing for cancer therapy targeted to the tumour microenvironment［J］.Nature,2015,518(7537):107-110.
[38] Ghajar CM.Metastasis prevention by targeting the dormant niche［J］.Nat Rev Cancer,2015,15(4):238-247.
[39] Woo JH,Shimoni Y,Yang WS,et al.Elucidating compound mechanism of action by network perturbation analysis［J］.Cell,2015,162(2):441-451.